AEON Biopharma, Inc. — Form 8-K
Filed July 15, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 62/100
What the filing says
AEON Biopharma entered into an underwriting agreement with Lake Street Capital Markets on July 13, 2026, to sell 17.85M shares of Class A common stock at $0.3221/share, plus 24.84M pre-funded warrants, 42.69M two-year milestone warrants ($0.3221 exercise), and 42.69M five-year milestone warrants ($0.3704 exercise), with a 15% overallotment option. The firm securities have a combined purchase price of $0.29953 per share plus warrants. Closing scheduled for July 15, 2026. Lake Street Capital Markets and Laidlaw Company (UK) Ltd are underwriters.
Why this rating
Large capital raise (~$5.4M) relative to ~$8.7M market cap is meaningful dilution (~195% of current shares if all exercised). Significant but typical warrant-heavy financing for biotech. Negative due to massive dilution.
See more from July 15, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.